Thinking about Mounjaro in Manchester? Here's what to weigh up first

Which access route fits your situation right now?

Manchester has NHS weight management services, but demand outstrips capacity across most of Greater Manchester's integrated care board area. The NHS route for tirzepatide follows the phased NICE rollout guidance — currently, eligibility for NHS prescribing of Mounjaro under TA1026 requires a BMI of 40 or above alongside four or more qualifying conditions, with broader cohorts being opened through 2026 and 2027. If you fall outside those thresholds today, or if your GP surgery has not yet opted into the new GP contract for weight management, the NHS path may not be open to you yet.

The alternative is a private route through a regulated online pharmacy. With a GPhC-registered service, a real prescriber (not an automated system) reads your consultation on the day you submit it and decides whether treatment is appropriate. If approved, the medicine is dispatched the same day for next-working-day delivery, arriving in plain packaging. There's no need to be seen in Manchester specifically; your prescriber is regulated by the same UK bodies regardless. You can verify any online pharmacy's registration through the GPhC pharmacy register before you commit to anything.

A third path exists for some people: a referral from their GP into a specialist weight management service. This usually involves longer timescales but comes with structured dietary and psychological support alongside the medicine, worth asking your GP about if that kind of wrap-around care appeals to you. If you've heard about the Manchester Mounjaro trial and want to know whether it might be relevant to your situation, that's also worth looking into alongside your other options. Exploring your weight-loss treatment options in full is a useful starting point if you're still at the research stage.

Are you likely to meet the clinical criteria?

Eligibility for Mounjaro is set by the medicine's licence, not by geography. A prescriber will look at your BMI, any weight-related conditions you have, and your broader health picture, including medicines you're already taking and any conditions that would make tirzepatide unsuitable. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance, so the 30 or 27 figures are starting points rather than absolute rules.

A few conditions mean Mounjaro isn't appropriate: pregnancy, breastfeeding, or actively trying to conceive rule it out. A personal or family history of medullary thyroid carcinoma or MEN2 is also a contraindication, as is a history of pancreatitis. The prescriber's job is to weigh all of this, it's the reason clinical assessment is required, not just a regulatory box to tick.

If you're transferring from a different provider and are already on a higher dose, evidence of your current treatment will be needed before a prescriber can continue it safely. Our frequently asked questions cover what transfer patients typically need to have ready.

What will it actually cost, and is the price complete?

Cost is a legitimate part of this decision, and it's worth asking the right questions before comparing providers. Since Eli Lilly raised Mounjaro's UK list price in September 2025, private treatment has typically ranged from roughly £149 to £375 per four-week pen depending on the dose and the provider, figures reported widely at the time. A fuller breakdown of Mounjaro pricing in the UK explains what drives that range and what to watch for.

The more important question is what the headline price includes. Some services charge separately for consultations, prescriptions, delivery, and follow-up support. At nume, one transparent price covers the consultation, prescription, treatment, and free next-working-day delivery by DPD, with prescriber aftercare available seven days a week. There are no subscriptions and no auto-renewals; every repeat order goes through a fresh clinical review. We don't enter the cheapest-on-the-page competition deliberately, the value is in the oversight, not the saving.

Tirzepatide is a prescription-only medicine. That framing matters when you see prices significantly below the market range: the MHRA's Yellow Card scheme invites the public to report suspected counterfeit sellers, and large seizures of fake pens (some containing insulin) underline why supply chain legitimacy sits above price as the right metric.

What does the day-to-day reality of treatment look like?

Manchester residents who start Mounjaro typically settle into a simple weekly routine. The pen lives in the fridge (the door shelf works fine) and the injection takes around a minute. Side effects are most common in the first week or two of a new dose and are mostly gastrointestinal: nausea, changes to appetite, loose stools, or reflux. They ease for most people as the body adjusts.

The thing prescribers hear most often from new patients is surprise at how quickly their appetite changes. That's the medicine's dual GIP and GLP-1 action working, not a signal to skip meals altogether, protein, fibre, and hydration matter more, not less, on treatment. Our guidance on eating well alongside Mounjaro has practical suggestions on this.

Some symptoms prompt a call to a doctor rather than watchful waiting. Severe stomach pain that reaches the back or doesn't settle is one; chest discomfort is another, and you can read more about what chest pain during Mounjaro treatment means and when to seek help. Dry heaving after a dose is also something patients ask about, what causes it and how to manage it is covered separately. You can also find out more about how tirzepatide works if the mechanism is part of what you want to understand before deciding.

If, after reading all of this, you'd like a clinician to review your situation properly, speaking to our prescribers is the natural next step. The consultation is free, there's no obligation, and the whole process begins online at a time that suits you.